The HARMONi-A study established that ivonescimab combined with chemotherapy significantly improved both PFS and OS, versus chemotherapy alone, in EGFR-positive NSCLC patients after progression on a third-generation EGFR-TKI, while maintaining a manageable safety profile (49, 50). This evidence concerns the gene EGFR and non-small cell lung carcinoma.